Results 151 to 160 of about 93,969 (303)

Reproxalap - A Novel Treatment Option for Allergic Conjunctivitis - A Comprehensive Narrative Review. [PDF]

Health Sci Rep
Mughal S, Awan RE, Abbas H, Sania Z, Habib A, Sakina SK, Mahmud A, Eljack MMF.   +7 more
europepmc   +1 more source

Clinical Laboratory Innovations: Nanoscale Detection of Chloramphenicol Using Nanomaterial Biosensors

Analytical Science Advances, Volume 7, Issue 2, December 2026.
Nanosensor schematic functionalized with specific bioreceptors that produce electrochemical signals upon Chloramphenicol binding. Resulting voltammetric readouts (differential pulse, square‐wave, and cyclic voltammetry) are analyzed to identify and quantify Chloramphenicol.
Nava Moghadasian Niaki, Reza Kheradmand, Seyedeh Giso Akbarian, Elham Shaterian, Hamed Shaterian, Ahmad Mobed   +5 more
wiley   +1 more source

Conjunctivitis in Neonates [PDF]

Infection Control, 1984
T W, Lane, F D, Ivey
openaire   +2 more sources

Recurrent Red Eye Misdiagnosed as Conjunctivitis: Ocular Rosacea With Corneal Neovascularization in a Young Patient. [PDF]

Cureus
Ferreira J, Embalo A, Rodrigues A, Cavaco S, Ferreira G.   +4 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

CONJUNCTIVITIS IN THE TROPICS [PDF]

BMJ, 1925
openaire   +2 more sources

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria. [PDF]

Dermatol Ther (Heidelb)
Yosipovitch G, Kim BS, Koo JY, Chen Z, Wiggins S, Zahn J, Sugerman P, Haddad EB, Cyr SL.   +8 more
europepmc   +1 more source

A 5‐Year Retrospective Morbidity Profile of School‐Aged Children at Ho Polyclinic, Volta Region, Ghana: Skin Conditions, Malaria, and Respiratory Illnesses as Leading Causes (2018–2022)

Public Health Challenges, Volume 5, Issue 3, September 2026.
Analysis of 10,428 outpatient consultations among school‐aged children attending Ho Polyclinic, Ghana (2018–2022), showed that three conditions accounted for 77.4% of all morbidity: skin conditions (38.3%), malaria (23.0%), and respiratory conditions (16.1%).
Anthoinette Adesope Ekuban, Frank Baiden
wiley   +1 more source

Recurrent acute bilateral cicatricial conjunctivitis as an adverse event of systemic adalimumab for rheumatoid arthritis. [PDF]

Digit J Ophthalmol
Matsou A, Zormpas S, Antunes D, McElvanney A.   +3 more
europepmc   +1 more source

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, Volume 104, Issue 6, Page e599-e614, September 2026.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source